Galeterone

Galeterone is a novel therapeutic agent under investigation for the treatment of prostate cancer. It is classified as an antiandrogen, specifically targeting the androgen receptor (AR) pathway, which plays a pivotal role in the development and progression of prostate cancer. Galeterone acts through multiple mechanisms of action, including inhibition of CYP17 lyase—an enzyme critical for androgen biosynthesis—antagonism of the androgen receptor, and degradation of the androgen receptor, distinguishing it from other therapies that target only a single aspect of the AR signaling pathway.

Mechanism of Action

Galeterone operates through a tri-modal mechanism of action, making it unique among prostate cancer treatments. Firstly, it inhibits the activity of CYP17 lyase, an enzyme essential for the production of androgens in the testes, adrenal glands, and prostate tumor itself. This inhibition reduces the overall levels of circulating androgens, limiting their availability to stimulate prostate cancer cells. Secondly, galeterone acts as an antagonist to the androgen receptor, preventing androgens from binding and activating the receptor, which is crucial for the growth and survival of prostate cancer cells. Lastly, it promotes the degradation of the androgen receptor, reducing the number of receptors available for activation.

Clinical Trials

Galeterone has been evaluated in several clinical trials for its safety and efficacy in treating patients with castration-resistant prostate cancer (CRPC), a stage of the disease where cancer progresses despite low levels of testosterone. Early-phase trials have demonstrated galeterone's potential in reducing prostate-specific antigen (PSA) levels, a marker of prostate cancer activity, and in managing CRPC patients, including those who have developed resistance to other AR-targeted therapies such as enzalutamide and abiraterone.

Development and Regulatory Status

As of the last update, galeterone is not yet approved by the U.S. Food and Drug Administration (FDA) or other regulatory bodies for the treatment of prostate cancer. Its development has seen various phases of clinical trials, with ongoing studies aimed at better understanding its efficacy and safety profile in a broader patient population. The future of galeterone will depend on the outcomes of these clinical trials and the regulatory review process.

Potential Implications for Prostate Cancer Treatment

The development of galeterone represents a significant advancement in the field of prostate cancer therapy, particularly for patients with CRPC who have limited treatment options. Its unique mechanism of action offers a promising approach to overcoming resistance to current AR-targeted therapies, potentially improving outcomes for patients with advanced prostate cancer.

See Also

• Androgen deprivation therapy
• Prostate cancer
• Castration-resistant prostate cancer
• CYP17 inhibitor
• Androgen receptor antagonist

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian